GlassScriptPhysician profile
Stephanie M Wolfe
NPI 1043505415
$5,529.88
in general payments reported to CMS, 2019-2025
31 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $105 · 2021: $531 · 2022: $866 · 2023: $633 · 2024: $2,245 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,061.21 |
| Travel and Lodging | $967.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,380.20 | 2020-2024 | Vns Therapy |
| Ucb, INC. | $1,325.26 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $464.49 | 2022-2025 | |
| Neurelis, INC. | $430.99 | 2021-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $282.97 | 2024-2025 | Motpoly Xr |
| Aquestive Therapeutics, INC. | $174.34 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $152.99 | 2021-2023 | Qelbree |
| Greenwich Biosciences, INC. | $123.15 | 2021 | |
| Acadia Pharmaceuticals INC | $121.74 | 2025 | Daybue |
| Gilead Sciences, INC. | $117.49 | 2024 | |
| Medtronic, INC. | $108.36 | 2023-2024 | Synchromedii |
| Tris Pharma INC | $107.24 | 2022-2025 | Onyda Xr |
| Corium, LLC | $92.70 | 2021-2022 | |
| Sk Life Science, INC. | $89.63 | 2025 | |
| Philips North America LLC | $56.90 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55.10 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $52.34 | 2023 | Lyvispah |
| Zogenix INC. | $47.38 | 2021 | |
| Biomarin Pharmaceutical INC. | $42.08 | 2022-2025 | Brineura |
| Biogen, INC. | $39.54 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $34.23 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $30.03 | 2022 | |
| Orchard Therapeutics North America | $28.12 | 2025 | Lenmeldy |
| Baxter Healthcare | $27.57 | 2023 | Hillrom - Synclara Cough System |
| Merck Sharp & Dohme LLC | $25.01 | 2025 | Winrevair |
| Amgen INC. | $24.00 | 2020 | |
| Sumitomo Pharma America, INC. | $22.19 | 2023 | Aptiom |
| Tersera Therapeutics LLC | $21.47 | 2022 | |
| Sarepta Therapeutics, INC. | $21.06 | 2021 | |
| Ptc Therapeutics, INC. | $21.02 | 2021 | |
| Metacel Pharmaceuticals LLC | $10.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.